Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TPH1 | P17752 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4943117 | 1.00 | GNPAT (0.49) | GNPATKMT2APPARGLMNAPPARA | |
| SCHEMBL18067342 | 0.85 | KMT2A (0.55) | KMT2APPARGLMNAPPARAACACB | |
| SCHEMBL28256323 | 0.85 | PLA2G10 (0.49) | GNPATKMT2ATDP1PTPN1CA2 | |
| SCHEMBL28256327 | 0.85 | PLA2G10 (0.49) | GNPATKMT2ATDP1PTPN1CA2 | |
| SCHEMBL2772723 | 0.83 | TDP1 (0.54) | GNPATKMT2APPARGPPARATDP1 | |
| SCHEMBL23604980 | 0.83 | ACACB (0.46) | KMT2APPARGLMNAPPARAACACB | |
| SCHEMBL25341206 | 0.82 | PRSS1 (0.50) | PTPN1CA2CA1ITGB3ITGA2B | |
| SCHEMBL17992600 | 0.82 | ACACB (0.48) | KMT2APPARGLMNAPPARAACACB | |
| SCHEMBL23917908 | 0.82 | KMT2A (0.47) | KMT2APPARGLMNAPPARAACACB | |
| SCHEMBL28787374 | 0.81 | L3MBTL1 (0.51) | GNPATTDP1PTPN1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282418-B1 | USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-17 | — | — | EP | claimed |
| US-6914069-B2 | Pharmaceutically active compounds and methods of use | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-07-05 | — | — | US | claimed |
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2024015229-A1 | PROTEASE/ENZYME CLEAVABLE LINKER-PAYLOADS AND PROTEIN CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024006272-A1 | β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF | SUTRO BIOPHARMA, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-10844090-B2 | Hemiasterlin derivatives for conjugation and therapy | SUTRO BIOPHARMA, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-7456201-B2 | Pharmaceutically active compounds and methods of use | LABORATOIRES SERONO SA (CH) | 2008-11-25 | — | — | US | disclosed |
| EP-1441724-B8 | METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS | SERONO LAB (CH) | 2007-10-17 | — | — | EP | disclosed |
| EP-1441724-B1 | METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS | APPLIED RESEARCH SYSTEMS (AN) | 2007-09-05 | — | — | EP | disclosed |
| EP-1282418-B1 | USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-17 | — | — | EP | disclosed |
| US-6914069-B2 | Pharmaceutically active compounds and methods of use | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-07-05 | — | — | US | disclosed |
| US-20050026985-A1 | Pharmaceutically active compounds and methods of use | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. | 2005-02-03 | — | — | US | disclosed |
| US-20040198799-A1 | Methods of increasing endogenous testosterone levels | LABORATOIRES SERONO SA (CH) | 2004-10-07 | — | — | US | disclosed |
| EP-1441724-A1 | METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS | Applied Research Systems ARS Holding S.A. (AN) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003026649-A1 | METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-04-03 | — | — | WO | disclosed |
| EP-1282418-A2 | USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY | Serono Reproductive Biology Institute, Inc. (US) | 2003-02-12 | — | — | EP | disclosed |
| US-20020132844-A1 | Pharmaceutically active compounds and methods of use | MERCK SERONO SA (CH) | 2002-09-19 | — | — | US | disclosed |
| WO-2001087287-A2 | USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | GNPAT 4347/4885KMT2A 3176/4885PPARG 3910/4885 |
| US-20040198799-A1 | Methods of increasing endogenous testosterone levels | SHBG, CYP17A1, NR5A1 | GNPAT 788/4885KMT2A 2565/4885PPARG 392/4885 |
| US-10844090-B2 | Hemiasterlin derivatives for conjugation and therapy | CYP17A1, HSD17B7, SHBG | GNPAT 210/4885KMT2A 2712/4885PPARG 2401/4885 |
| US-20020132844-A1 | Pharmaceutically active compounds and methods of use | CATSPER1, NASP, ACR | GNPAT 940/4885KMT2A 3050/4885PPARG 205/4885 |
| US-20050026985-A1 | Pharmaceutically active compounds and methods of use | CATSPER1, NASP, ACR | GNPAT 940/4885KMT2A 3050/4885PPARG 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.